InvestorsHub Logo
Followers 86
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: Carboat post# 120331

Saturday, 04/27/2013 9:29:26 AM

Saturday, April 27, 2013 9:29:26 AM

Post# of 346054

Sure a stock may be slightly undervalued at a given time, but if you think a stock priced at $1.39 is really worth $30, and only you and a few other ihub board members are smart enough to know this,and the rest of the scientific and investment comunity has it wrong...



You didn't read the Market Review for SOC Lung cancer $4B so you must start there.

1) True... current value is at $1.39

2) You must place future value with SOC (FDA approvals and 1st line at 14+ months MOS coming in under 45 days <<< this is the key that everyone must realize.... in 45 days or less is all the time the opposition has to work with at the most

3) This is "conservative" market value $4B = $30 pps

4) Unfortunately... many institutional players can't touch the stock under $5... $4... sometimes $3 so they must wait for the news

5) Smaller Retail Investors do not have to wait for the news!!!!

6) If hedge funds are being advised by anyone .... they were told "SOMETHING" that forced them to do something at CSM in Fargo, ND

7) If BP's in partnering talks were told something... there was "SOMETHING" done that tried to take Peregrine out in mid-flight last September 24 at CSM in Fargo, ND

8) Guess who created an account September 25 at 2:40 a.m. just hours after our bird was taken out mid-flight ? Carboats 1st post that describes the oppositions plan which backfired

9) The peregrine is back in the air.... now the "opposition" is trying to say she can't fly high enough nor fast enough

I beg to differ.. and if whats the bottom line? If you believe in FDA positive decisions are coming for phase IIB NSCLC and 14+ months MOS improvement in 1st line NSCLC... then you will see a market cap of $4B.

*** Remember... this is just the starting point. I am not going to even factor in Peregrine showing up at ASCO with positive breast cancer results... any complete responses? we fly higher... any interesting sub-analysis of Pancreatic cancer trial such as it works on ECOG 0/1 ?? we fly higher...

GLTA!

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News